1-di(sec-butyl)phosphinoylhexane | 52911-10-1

• 分子结构分类: 有机化合物 - 有机磷化合物 - 有机膦及其衍生物
• 英文名称: 1-di(sec-butyl)phosphinoylhexane
• 英文别名: 1-di-sec-butylphosphoryl hexane；Disec-butyl-n-hexyl-phosphine oxide；1-di(butan-2-yl)phosphorylhexane
• CAS: 52911-10-1
• 化学式: C₁₄H₃₁OP
• 分子量: 246.373
• InChiKey: RSFUTVOECBDVJD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  16
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  Di-sec.-butylphosphinsaeurechlorid 、 己基溴化镁 以 四氢呋喃 为溶剂， 反应 18.0h， 生成 1-di(sec-butyl)phosphinoylhexane
  参考文献：
  名称：

  Ophthalmic compositions and method for treating eye discomfort and pain

  摘要：

  通过给眼科溶液滴加含有三烷基氧化膦的创新组合物的眼药水，可以减少眼部不适。首选的给药方法是将溶液滴在闭合眼睛的内眼角，并保持眼睛闭合至少一分钟。优选的三烷基氧化膦是因为其强效性、长效性和无刺激性而被选择。为了进一步减少刺激性，可以向组合物中添加碳氢化合物聚醇或类似的润滑剂。在眼科溶液中的三烷基氧化膦的浓度最好在至少约0.001重量％至约0.5％（10μg/ml至5毫克/毫升）的组合物中。

  公开号：

  US20050059639A1

文献信息

• Di-isopropyl-phosphinoyl-alkanes as topical agents for the treatment of sensory discomfort
  申请人：Wei Edward T.

  公开号：US20150164924A1

  公开（公告）日：2015-06-18

  The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to certain di-isopropyl-phosphinoyl-alkanes as described herein, DIPA-1-5, DIPA-1-6, DIPA-1-7, DIPA-1-8, and DIPA-1-9, collectively referred to herein as “DIPA compounds”, that are useful, for example, in the treatment of disorders (e.g., diseases) including: sensory discomfort (e.g., caused by irritation, itch, or pain); a skin dysesthesia; dermatitis; ocular pain and discomfort; heat discomfort; heat stress; flushing and/or night sweats (vasomotor symptoms); post-operative hypothermia; post-anaesthetic shivering; fatigue; tiredness; depression; cognitive dysfunction; and to enhance cognitive function. The applicant has found that localized delivery of DIPA compounds to the upper eyelid and/or facial skin has an alerting and enhancement effect on behavior and can be used to give a cosmetic refreshing look, to mental alertness, to reduce fatigue, and to improve work output. The present discovery also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, for example, in therapy, in diagnosis of neuropathic pain, and in study of TRPM8 function.

  本发现通常涉及治疗化合物领域。更具体地，本发现涉及如下所述的某些二异丙基磷酰基烷烃，即DIPA-1-5、DIPA-1-6、DIPA-1-7、DIPA-1-8和DIPA-1-9，以下统称为“DIPA化合物”，这些化合物在治疗包括但不限于感觉不适（例如由刺激、瘙痒或疼痛引起）、皮肤感觉异常、皮炎、眼部疼痛和不适、热感不适、热应激、潮红和/或盗汗（血管运动症状）、术后低体温、麻醉后颤抖、疲劳、疲倦、抑郁、认知功能障碍以及增强认知功能等疾病（例如疾病）的治疗中具有用途。申请人发现将DIPA化合物局部传递至上眼睑和/或面部皮肤对行为具有警觉和增强效果，并可用于给予一种化妆上的焕然一新的外观，提高精神警觉度，减轻疲劳，并提高工作产出。本发现还涉及包含此类化合物的药物组合物，以及此类化合物和组合物的用途，例如在治疗、神经病痛诊断和TRPM8功能研究中的应用。
• Chemical inhibitors of sebocyte function
  申请人：Wei Edward T.

  公开号：US20170240575A1

  公开（公告）日：2017-08-24

  The present discovery pertains to the discovery of certain amphiphilic compounds that may be useful for the management of sebum secretion in subjects with acne, oily skin, or seborrheic dermatitis. These compounds are 1-dialkylphosphorylalkanes with the longest alkyl group being seven or more carbons. Preferably, a compound is dissolved in a dermatologically acceptable vehicle, and delivered to the skin in a solution, gel, lotion, cream, or ointment. The method of application may be with the surface of the finger, or via an applicator. The decrease is sebum secretion in certain subjects may result in skin conditions that enhance cosmetic appearance and ameliorate skin disorders.

  这项发现涉及到某些两性分子化合物的发现，这些化合物可能对患有痤疮、油性皮肤或脂溢性皮炎的人群的皮脂分泌管理有用。这些化合物是1-二烷基磷酰基烷烃，其中最长的烷基基团含有七个或更多碳原子。最好将化合物溶解在皮肤学上可接受的载体中，并以溶液、凝胶、乳液、霜剂或软膏的形式送达到皮肤上。应用方法可以是用手指表面，或通过一个涂抹器。减少某些人群的皮脂分泌可能导致增强化妆效果和改善皮肤疾病的皮肤状况。
• Cooling adjunct for medications to treat disorders in the nasal cavity
  申请人：Wei Edward Tak

  公开号：US10722477B2

  公开（公告）日：2020-07-28

  The present discovery pertains generally to the field of therapeutic compounds. More specifically the present discovery pertains to certain di-alkyl-phosphinoyl-alkanes as described herein, DIPA-1-8 and DIPA-1-9, and 2-6 and 2-7 that are collectively referred to herein as “DAPA compounds”, that are useful in the treatment of disorders (e.g., diseases) including: sensory discomfort (e.g., caused by inflammation, irritation, itch, or pain) in the nasal cavity. The applicant has found that localized delivery of DAPA compounds in combination with an intranasal steroid or an intranasal antihistamine immediately relieves nasal discomfort and enhances patient adherence to the use of the nasal medications.

  本发现一般涉及治疗化合物领域。更具体地说，本发现涉及本文所述的某些二烷基膦酰基烷烃、DIPA-1-8 和 DIPA-1-9，以及本文统称为 "DAPA 化合物 "的 2-6 和 2-7，这些化合物可用于治疗包括鼻腔感觉不适（如由炎症、刺激、瘙痒或疼痛引起）在内的紊乱（如疾病）。申请人发现，局部给药 DAPA 化合物与鼻内类固醇或鼻内抗组胺药结合使用，可立即缓解鼻腔不适，并提高患者使用鼻腔药物的依从性。
• Method to reduce face mask and respirator discomfort
  申请人：Wei Edward Tak

  公开号：US11389462B2

  公开（公告）日：2022-07-19

  Wearing a face mask or a filtering facepiece respirator, especially in hot weather for more than one hour, causes discomfort. But, in a viral pandemic, a barrier to filter inhaled and exhaled air is necessary to protect against airborne pathogens. The sensations of heat abstraction, that is, coolness and cold, can be captured by the rational design of optimized molecules. The topical application of these molecules alleviates the discomfort of wearing a face mask covering. Several entities were identified by synthesis and experiment as having the ideal properties for achieving this purpose. The preferred embodiments are certain 1-diisopropyl-phosphinoyl-alkanes described as DIPA-1-7, DIPA-1-8, and DIPA-1-9, collectively referred to herein as “DIPA compounds.” The applicant found that topical delivery of DIPA compounds to the facial skin, especially to the surface of the external nares (nostrils), alleviates face mask discomfort. From these studies, I hypothesize that the absence of cool air dynamics about the nostrils causes face mask discomfort, not just static heat accumulation or excess humidity. The present discovery pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions for relieving face mask discomfort.

  戴口罩或过滤式面罩呼吸器，尤其是在炎热的天气下超过一个小时，会引起不适。但是，在病毒大流行的情况下，为了防止空气中的病原体，有必要使用屏障来过滤吸入和呼出的空气。通过合理设计优化分子，可以捕捉到热量吸收的感觉，即凉爽和寒冷的感觉。这些分子的局部应用可减轻戴口罩的不适感。通过合成和实验，确定了几种实体具有实现这一目的的理想特性。优选的实施方案是某些 1-二异丙基-膦酰-烷烃，描述为 DIPA-1-7、DIPA-1-8 和 DIPA-1-9，在此统称为 "DIPA 化合物"。申请人发现，将 DIPA 化合物外敷于面部皮肤，尤其是外鼻（鼻孔）表面，可以减轻面膜带来的不适感。根据这些研究，我推测是鼻孔周围缺乏冷空气动力导致了面罩不适，而不仅仅是静态热量积聚或湿度过大。本发现涉及包含此类化合物的药物组合物，以及使用此类化合物和组合物缓解面罩不适的方法。
• TRP-P8 ACTIVE COMPOUNDS AND THERAPEUTIC TREATMENT METHODS
  申请人：Genentech, Inc.

  公开号：EP1656144B2

  公开（公告）日：2017-12-20